147 related articles for article (PubMed ID: 35016411)
1. Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer.
Tan A; Wang H; Nong L; Jia Y; Liu Y; Zhong W; Qin F; Wang H; Tang J; Zhou W; Lu Y; Xie W
Ann Palliat Med; 2021 Dec; 10(12):12101-12112. PubMed ID: 35016411
[TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients.
Huang W; Liu J; Wu F; Chen K; Li N; Hong Y; Huang C; Zhen H; Lin L
Oncotarget; 2016 May; 7(21):31501-7. PubMed ID: 27129172
[TBL] [Abstract][Full Text] [Related]
4. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Chen Y; Guan Y; Wang J; Ma F; Luo Y; Chen S; Zhang P; Li Q; Cai R; Li Q; Mo H; Lan B; Chen X; Zhao W; Xu B; Fan Y
Int J Cancer; 2020 Dec; 147(12):3490-3499. PubMed ID: 32588429
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
6. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial.
Zhao Y; Zhang X; Jin C; Yu X; Zhang M; Cao Y; Li Y; Wang A; Shan X; Zhang J; Wang J; Yin L; Tan X; Liu J
Ann Palliat Med; 2021 Mar; 10(3):3277-3285. PubMed ID: 33849112
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Lu S; Li L; Luo Y; Zhang L; Wu G; Chen Z; Huang C; Guo S; Zhang Y; Song X; Yu Y; Zhou C; Li W; Liao M; Li B; Xu L; Chen P; Hu C; Hu C
J Thorac Oncol; 2015 Jan; 10(1):206-11. PubMed ID: 25654728
[TBL] [Abstract][Full Text] [Related]
10. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
Yang R; Shi YY; Han XH; Liu S
Oncol Res Treat; 2021; 44(6):333-343. PubMed ID: 33975311
[TBL] [Abstract][Full Text] [Related]
13. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
14. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
17. Platinum-based chemotherapy in triple-negative advanced breast cancer.
Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
Breast Cancer Res Treat; 2014 Aug; 146(3):567-72. PubMed ID: 25001611
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
19. Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.
Hu Z; Sun S; Zhao X; Yu H; Wu X; Wang J; Chang J; Wang H
Oncologist; 2022 Apr; 27(4):253-e312. PubMed ID: 35380726
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.
Chen L; Tong F; Peng L; Huang Y; Yin P; Feng Y; Cheng S; Wang J; Dong X
Radiother Oncol; 2022 Sep; 174():44-51. PubMed ID: 35788355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
